<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Retrovirology</journal-id><journal-title>Retrovirology</journal-title><issn pub-type="epub">1742-4690</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">1716897</article-id><article-id pub-id-type="publisher-id">1742-4690-3-S1-P73</article-id><article-id pub-id-type="doi">10.1186/1742-4690-3-S1-P73</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentations</subject></subj-group></article-categories><title-group><article-title>Virological responses of treatment-naïve stage CDC-2 HIV-1 positive subjects receiving VGV-1 injections in a blinded, placebo-controlled, multi-centre clinical trial</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Noveljic</surname><given-names>Zoja</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A2" contrib-type="author"><name><surname>Zhabilov</surname><given-names>Harry</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A3" contrib-type="author"><name><surname>Hwang</surname><given-names>Jimmy</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib id="A4" contrib-type="author"><name><surname>Clark</surname><given-names>Anel</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib id="A5" contrib-type="author"><name><surname>Louw</surname><given-names>AnneRika</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib id="A6" contrib-type="author"><name><surname>Wright</surname><given-names>Timothy</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib id="A7" corresp="yes" contrib-type="author"><name><surname>Bouic</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I6">6</xref></contrib></contrib-group><aff id="I1"><label>1</label>Tiervlei Clinical Trial Center, Cape Town, South Africa</aff><aff id="I2"><label>2</label>Viral Genetics, Inc., Azusa, California, USA</aff><aff id="I3"><label>3</label>University of California, San Francisco, California, USA</aff><aff id="I4"><label>4</label>Synexa Life Sciences, Limited, Cape Town, South Africa</aff><aff id="I5"><label>5</label>Viral Genetics South Africa, Limited, South Africa</aff><aff id="I6"><label>6</label>University of Stellenbosch, Cape Town, South Africa</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>21</day><month>12</month><year>2006</year></pub-date><volume>3</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">2006 International Meeting of The Institute of Human Virology</named-content><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/content/pdf/1742-4690-3-S1-info.pdf">http://www.biomedcentral.com/content/pdf/1742-4690-3-S1-info.pdf</ext-link></supplement><fpage>P73</fpage><lpage>P73</lpage><permissions><copyright-statement>Copyright © 2006 Noveljic et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Noveljic et al; licensee BioMed Central Ltd.</copyright-holder></permissions><conference><conf-date>17–21 November 2006</conf-date><conf-name>2006 International Meeting of The Institute of Human Virology</conf-name><conf-loc>Baltimore, USA</conf-loc></conference></article-meta></front><body><sec><title><offsets xml_i="3663" xml_f="3673" txt_i="7" txt_f="17">Background</offsets></title><p><offsets xml_i="3684" xml_f="3964" txt_i="18" txt_f="295">A blinded, placebo-controlled, multi-center study was completed in South Africa to determine virological response of treatment-naïve CDC-2 HIV-1 infected subjects receiving VGV-1 injections. The primary endpoint was the proportion of subjects with &gt;0.5 log decrease in HIV-RNA.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="4005" xml_f="4012" txt_i="297" txt_f="304">Methods</offsets></title><p><offsets xml_i="4023" xml_f="4438" txt_i="305" txt_f="720">138 subjects with mean CD4 of 336 cells/ul and mean HIV-RNA of 4.9 log were enrolled in this GCP, ICH-compliant study. Subjects were randomized to receive either VGV-1 monotherapy (bovine-derived thymus nuclear protein in alum, presumable immune modulator) or control via 16 biweekly i.m. injections and followed to 240 days. Effects of antiretrovirals, provided to disease progressors, were excluded from analysis.</offsets></p></sec><sec><title><offsets xml_i="4460" xml_f="4467" txt_i="722" txt_f="729">Results</offsets></title><p><offsets xml_i="4478" xml_f="4975" txt_i="730" txt_f="1224">Statistically significant antiviral responses were observed in treated subjects versus placebo (22.2% vs. 6.25%, p = 0.024) 100 days after dosing (day 150). Effects waned (15.6% vs. 6.25%, p = 0.128) 190 days after dosing (day 240). Antiviral responses were more common in immune-compromised (baseline CD4&lt;300 cells/ul) subjects at day 150 (35.7%, p = 0.019) and day 240 (25%, p = 0.0479) compared to placebo. There were no serious adverse events observed in relation with the VGV-1 injections.</offsets></p></sec><sec><title><offsets xml_i="4997" xml_f="5007" txt_i="1226" txt_f="1236">Conclusion</offsets></title><p><offsets xml_i="5018" xml_f="5193" txt_i="1237" txt_f="1412">Bioactivity of VGV-1 was confirmed and it was well tolerated without apparent safety concerns vs. control. Further study to optimize dosing and clarify mechanism is warranted.</offsets></p></sec></body></article>